De-Risking Cardiac AI: AEMS for Software Failure Prediction

The FDA’s Manufacturer and User Facility Device Experience (MAUDE) database has been consolidated into the new Adverse Event Monitoring System (AEMS) as of March 2026. Therefore, references to the MAUDE database and its search portal have been updated to reflect AEMS. The overall volume of adverse event reports has significantly increased, with an 84% rise from 1.57 million in 2020 to 2.89 million in 2025, supporting the article’s claim of a steady increase in software-related adverse event reports. The mentioned product codes (LLZ, QIH, PHT) remain relevant for identifying software-related medical devices. “`html
Uncovering competitor software failures before designing your own device can save millions in recall costs and significantly de-risk your market entry. The FDA’s Adverse Event Monitoring System (AEMS), often overlooked, offers a strategic advantage for digital health companies. By systematically analyzing this public repository of adverse event reports, quality assurance managers, risk officers, and competitive intelligence analysts can gain unparalleled insights into potential software pitfalls, informing more strong product development and regulatory strategies.

The Untapped Potential of AEMS for SaMD Risk Assessment

The FDA’s Adverse Event Monitoring System (AEMS) is the FDA’s repository for medical device reports (MDRs), which include adverse events potentially related to medical devices. While often viewed as a reactive postmarket surveillance tool, AEMS is a proactive goldmine for SaMD developers. Under 21 CFR Part 803 Medical Device Reporting, manufacturers, device user facilities, and even importers are mandated to report device malfunctions, serious injuries, or deaths potentially caused by a medical device. This complete data set, spanning decades, provides granular detail on failure modes, contributing factors, and reported patient outcomes. For SaMD, where the lines between software bugs and clinical harm can be subtle, understanding real-world performance is critical. The average annual growth rate of software-related adverse event reports in AEMS has been steadily increasing, underscoring the escalating complexity and potential impact of software failures in healthcare. This trend highlights the urgent need for developers to integrate AEMS analysis into their risk management frameworks. By examining reported incidents, companies can identify common software vulnerabilities, anticipate potential user errors, and benchmark the safety profiles of established players and emerging competitors.

Using AEMS for Competitive Intelligence: Lessons from Industry Leaders

Major medical device manufacturers like Medtronic and Abbott Laboratories have long understood the strategic value of monitoring AEMS. These industry giants don’t just report their own adverse events. They actively analyze competitor data to benchmark safety profiles, identify emerging risks, and inform their own product development roadmaps. For instance, a quality assurance manager at Medtronic might analyze AEMS reports for similar SaMD products from Abbott, looking for patterns in software malfunctions, usability issues, or integration problems that could influence their own design choices or postmarket surveillance plans. This practice isn’t limited to hardware-centric devices. As AI health tools become more prevalent, the insights from AEMS become even more important. A company developing an AI-powered diagnostic SaMD can examine reports related to similar devices, even those with different intended uses, to understand generic software failure modes, such as issues with data input, algorithmic drift, or user interface misinterpretations. This proactive approach allows for the incorporation of lessons learned from the broader industry into internal risk assessments, potentially mitigating future recalls or costly postmarket corrections.

A Step-by-Step Guide to Querying Software Product Codes in AEMS

Working through AEMS effectively requires a systematic approach. The FDA provides various access portals, including a user-friendly search interface and a more strong downloadable data set for advanced analysis FDA AEMS search portal. For SaMD, identifying relevant reports often begins with understanding the specific product codes associated with software as a medical device. Here’s a methodological guide for quality assurance managers and risk officers: 1. Identify Relevant Product Codes: Begin by identifying FDA product codes specific to SaMD or software components within medical devices. Common codes include:

• LLZ: Medical Device Data System (MDDS), While MDDS was reclassified, reports under this code can still offer insights into data management software issues.
• QIH: Software, Medical, Image Processing, Relevant for AI tools analyzing medical images.
• PHT: Software, Medical, Diagnostic, A broad category that often includes various diagnostic SaMD. * It is important to consult the FDA’s Product Classification database to find the most accurate and current codes relevant to your specific device type FDA Product Classification Database. Search for keywords related to your SaMD’s function (e.g., “artificial intelligence,” “machine learning,” “diagnostic software”). 2. Formulate Search Queries: Use the AEMS search interface to combine product codes with keywords related to software failures. Examples include: `Product Code: QIH AND (software OR algorithm OR “artificial intelligence” OR “machine learning”) AND (error OR malfunction OR bug OR “false positive” OR “false negative”)` `Product Code: PHT AND (data integrity OR interface OR “user error” OR “system crash”)` 3. Filter and Refine Results: AEMS allows filtering by manufacturer, date reported, event type (malfunction, injury, death), and device problem. Focus on “malfunction” reports first, as they often provide the most direct insights into software defects. Pay close attention to the “Device Problem” and “Event Description” fields, which contain free-text narratives detailing the incident. 4. Analyze Failure Modes and Root Causes:
• Categorize Software Issues: Group similar reports to identify recurring software failure modes (e.g., data processing errors, display anomalies, integration failures, algorithmic misinterpretations, cybersecurity vulnerabilities).
• Identify Contributing Factors: Look for patterns in reported contributing factors, such as specific operating system versions, integration with third-party systems, user interaction errors, or environmental conditions.
• Assess Clinical Impact: Evaluate the reported clinical consequences of these software failures. Did they lead to delayed diagnoses, incorrect treatments, or workflow disruptions? This helps in prioritizing risk mitigation efforts. 5. Benchmark Competitor Performance: Analyze reports associated with competitors’ SaMD products. This provides an objective view of their real-world performance and can highlight areas where your own development can differentiate itself through superior safety and reliability. For example, if a competitor’s AI diagnostic tool frequently reports issues with specific data input formats, your team can proactively design a more strong data ingestion pipeline.
  

  Methodology and Source Note

The insights and search methodology presented here are developed from publicly available FDA CDRH (Center for Devices and Radiological Health) database tutorials and the detailed guidelines outlined in 21 CFR Part 803 Medical Device Reporting. This systematic approach helps digital health companies to transform a regulatory compliance database into a powerful strategic asset for proactive risk management and competitive intelligence. Understanding and using AEMS data is no longer optional. It is a critical component of designing safer, more effective, and commercially viable AI health tools. FDA CDRH Medical Device Reporting resources By integrating AEMS analysis into your quality management system and product development lifecycle, your organization can move beyond reactive problem-solving to a proactive stance, anticipating and mitigating risks before they impact patients or market reputation. This strategic use of public data is essential for any company aiming to lead in the highly regulated and rapidly evolving field of AI health.
“`